New hope for brain metastases? drug niraparib tested in small trial

NCT ID NCT04992013

Ongoing Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study tests the drug niraparib in 20 people whose cancer has spread to the brain or spinal cord. The goal is to see if the drug can shrink or control these tumors. Participants must have mild or no symptoms from their brain metastases and not need increasing steroids or seizure meds.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

central nervous system cancer metastatic malignant neoplasm Neoplasm Metastasis ovarian cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CENTRAL NERVOUS SYSTEM CANCER METASTATIC CANCER

Contacts and locations

Locations

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.